Preclinical study of formulated recombinant nucleocapsid protein, the receptor binding domain of the spike protein, and truncated spike (S1) protein as vaccine candidates against COVID-19 in animal models
Authors:
- 23 June 2022
- journal article
- research article
- Published by Elsevier in Molecular Immunology
- Vol. 149, 107-118
Abstract
No abstract availableKeywords
Funding Information
- Baqiyatallah University of Medical Sciences (5121)
This publication has 60 references indexed in Scilit:
- Recombinant receptor-binding domain of SARS-CoV spike protein expressed in mammalian, insect and E. coli cells elicits potent neutralizing antibody and protective immunityVirology, 2009
- Expression and Purification of a Recombinant Adenovirus Fiber Knob in a Baculovirus SystemIntervirology, 2008
- Receptor-binding domain of SARS-CoV spike protein induces long-term protective immunity in an animal modelVaccine, 2007
- Vaccine Efficacy in Senescent Mice Challenged with Recombinant SARS-CoV Bearing Epidemic and Zoonotic Spike VariantsPLOS Medicine, 2006
- Cloning, purification, and characterization of a non-collagenous anti-angiogenic protein domain from human α1 type IV collagen expressed in Sf9 cellsProtein Expression and Purification, 2006
- Immunological characterizations of the nucleocapsid protein based SARS vaccine candidatesVaccine, 2006
- Comparison of SUMO fusion technology with traditional gene fusion systems: Enhanced expression and solubility with SUMOProtein Science, 2006
- The development of vaccines against SARS corona virus in mice and SCID-PBL/hu miceVaccine, 2005
- Antibody Response of Patients with Severe Acute Respiratory Syndrome (SARS) Targets the Viral NucleocapsidThe Journal of Infectious Diseases, 2004
- NEUTRALIZING ANTIVIRAL B CELL RESPONSESAnnual Review of Immunology, 1997